Indivior Pharmaceuticals (NASDAQ: INDV) insider transactions

In the twelve months to 10 November 2026, executives and directors of Indivior Pharmaceuticals reported 3 open-market sales of 73,172 shares ($2.8m) and 10 open-market purchases of 8,850 shares ($311,556), by 9 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Indivior Pharmaceuticals shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
27 August 2026	Anderson Woodrow D	Chief Accounting Officer	Open-market purchase	+1,500	$35.69	27,638	Form 4
5 August 2026	Anderson Woodrow D	Chief Accounting Officer	Open-market purchase	+1,500	$36.28	26,138	Form 4
10 July 2026	Heidbreder Christian	Chief Scientific Officer	Open-market sale, 10b5-1 plan	−18,586	$41.14	209,337	Form 4
22 June 2026	Ciaffoni Joseph	Chief Executive Officer	Option exercise	+1,266,903	—	1,402,879	Form 4
22 June 2026	Ciaffoni Joseph	Chief Executive Officer	Shares withheld for tax	−612,549	$38.32	790,330	Form 4
11 June 2026	Heidbreder Christian	Chief Scientific Officer	Open-market sale, 10b5-1 plan	−18,586	$38.06	227,923	Form 4
8 June 2026	Preblick Ryan	Chief Financial Officer	Open-market sale, 10b5-1 plan	−36,000	$37.70	284,751	Form 4
13 May 2026	Ninivaggi Daniel A	Director	Grant or award	+6,518	—	27,163	Form 4
13 May 2026	Kingsley Stuart A	Director	Grant or award	+6,518	—	12,100	Form 4
13 May 2026	Stejbach Mark	Director	Grant or award	+6,518	—	27,087	Form 4
13 May 2026	Thompson Juliet	Director	Grant or award	+6,518	—	12,973	Form 4
13 May 2026	Wheadon David E.	Director	Grant or award	+10,430	—	30,780	Form 4
13 May 2026	Ryan Barbara	Director	Grant or award	+6,518	—	12,242	Form 4
13 May 2026	Humphreys Keith	Director	Grant or award	+6,518	—	16,042	Form 4
12 May 2026	Thompson Juliet	Director	Shares withheld for tax	−1,117	$38.28	6,455	Form 4
14 March 2026	Preblick Ryan	Chief Financial Officer	Option exercise	+6,302	—	323,594	Form 4
14 March 2026	Preblick Ryan	Chief Financial Officer	Shares withheld for tax	−2,843	$31.11	320,751	Form 4
13 March 2026	Ryan Barbara	Director	Open-market purchase	+8	$31.09	5,724	Form 4
9 March 2026	Ryan Barbara	Director	Open-market purchase	+31	$32.56	5,716	Form 4
6 March 2026	Kingsley Stuart A	Director	Open-market purchase	+940	$31.87	5,582	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Indivior Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.